Novo Nordisk's experimental obesity drug amycretin, targeting the amylin hormone, demonstrated significant weight loss in early clinical trials but showed similar efficacy across different dosing levels. Phase 1/2 results revealed a weight loss of 24.3% at the highest 60 mg dose, with overlapping weight-loss curves observed at lower doses. These findings, from a study published in The Lancet and presented at the American Diabetes Association conference, raise questions about the optimal dosing strategy for this promising therapy.